These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27217031)

  • 21. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SIDECAR project: S-IcD registry in European paediatriC and young Adult patients with congenital heaRt defects.
    Silvetti MS; Bruyndonckx L; Maltret A; Gebauer R; Kwiatkowska J; Környei L; Albanese S; Raimondo C; Paech C; Kempa M; Fésüs G; Knops RE; Blom NA; Drago F
    Europace; 2023 Feb; 25(2):460-468. PubMed ID: 36107451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death.
    Sanghera R; Sanders R; Husby M; Bentsen JG
    Ann N Y Acad Sci; 2014 Nov; 1329():1-17. PubMed ID: 25308791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers.
    Pettit SJ; McLean A; Colquhoun I; Connelly D; McLeod K
    Pacing Clin Electrophysiol; 2013 Dec; 36(12):1532-8. PubMed ID: 24033753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience of combined HeartWare ventricular assist device and implantable cardioverter defibrillator therapy.
    Pecha S; Wilke I; Bernhardt A; Hakmi S; Yildirim Y; Steven D; Reichenspurner H; Willems S; Deuse T; Aydin A
    J Cardiovasc Electrophysiol; 2014 Oct; 25(10):1109-14. PubMed ID: 24862733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease.
    Khanna AD; Warnes CA; Phillips SD; Lin G; Brady PA
    Am J Cardiol; 2011 Sep; 108(5):729-34. PubMed ID: 21684513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current indications for an implantable cardioverter defibrillator (ICD)].
    Arenja N; Schaer B; Sticherling C; Kühne M
    Ther Umsch; 2014 Feb; 71(2):111-6. PubMed ID: 24463381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The subcutaneous cardioverter-defibrillator: When less is more].
    Kuschyk J; Rudic B; Akin I; Borggrefe M; Röger S
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):123-8. PubMed ID: 26058997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A life-saving shock from a subcutaneous ICD during skydiving].
    Baumann S; Roeger S; Becher T; Akin I; Borggrefe M; Kuschyk J
    Herzschrittmacherther Elektrophysiol; 2017 Mar; 28(1):64-66. PubMed ID: 28185079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.
    Olde Nordkamp LR; Dabiri Abkenari L; Boersma LV; Maass AH; de Groot JR; van Oostrom AJ; Theuns DA; Jordaens LJ; Wilde AA; Knops RE
    J Am Coll Cardiol; 2012 Nov; 60(19):1933-9. PubMed ID: 23062537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience.
    Schuler PK; Herrey A; Wade A; Brooks R; Peebles D; Lambiase P; Walker F
    Europace; 2012 Dec; 14(12):1740-5. PubMed ID: 22744770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution.
    Jarman JW; Lascelles K; Wong T; Markides V; Clague JR; Till J
    Eur Heart J; 2012 Jun; 33(11):1351-9. PubMed ID: 22408031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.